Figure 1. . FSCN1 serum values in study population.

(A) The serum FSCN1 levels in prostate cancer patients (cases) versus controls by applying Mann–Whitney test in order to compare the median FSCN1 serum levels between the two groups. (B) The levels of FSCN1 for Gleason score groups in PCa patients when compared with controls performing Kruskal–Wallis test to determine the statistically significant difference between the medians of Gleason score groups. (C) The negative correlation (Spearman test) between FSCN1 and age for the control group (rho = -0.331; p = 0.009).